Application of ZFP36 gene in preparation of drugs for resisting abdominal aortic aneurysm

By constructing a mouse model of ZFP36 gene knockout and overexpression, it was discovered that the key role of ZFP36 gene in inhibiting abdominal aortic aneurysm was found, and the ZFP36 gene was overexpressed by adeno-associated virus (AAV2-ZFP36), which solved the lack of effectiveness in the prior art. The drug problem has achieved significant inhibition of the incidence and progress of abdominal aortic aneurysms.

CN119040335APending Publication Date: 2024-11-29SHANDONG UNIV QILU HOSPITAL
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411165045.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art lacks effective drugs to treat and delay the progression of abdominal aortic aneurysms, and the pathophysiological basis of smooth muscle cells in AAA has not been fully understood.

Method used

By constructing a mouse model that specifically knocked out the ZFP36 gene for smooth muscle, it was discovered that the role of the ZFP36 gene in anti-abdominal aortic aneurysm was performed, and the ZFP36 gene was overexpressed by adeno-associated virus (AAV2-ZFP36), significantly inhibiting the onset of abdominal aortic aneurysm. and progress.

Benefits of technology

Overexpressing the ZFP36 gene can effectively reduce the incidence of abdominal aortic aneurysms and inhibit its development, providing a theoretical basis for the preparation or screening of drugs that promote the expression of ZFP36 gene in smooth muscle cells, significantly inhibiting the tumorigenesis of mice abdominal aortic aneurysms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040335A_ABST
    Figure CN119040335A_ABST
Patent Text Reader

Abstract

The invention relates to application of a ZFP36 gene in preparation of an abdominal aortic aneurysm resisting medicine. According to the invention, a mouse is knocked out by constructing a gene of which smooth muscle specifically knockout ZFP36, and a mouse abdominal aortic aneurysm model is constructed by subcutaneously pumping AngII, so that the morbidity of abdominal aortic aneurysm can be obviously increased after the ZFP36 gene is knocked out, and the morbidity of abdominal aortic aneurysm can be effectively reduced and the occurrence and development of abdominal aortic aneurysm can be inhibited by overexpressing the ZFP36 gene; the invention provides a theoretical basis for preparing or screening drugs or preparations for promoting smooth muscle cell ZFP36 gene expression as alternative drugs or preparations for resisting abdominal aortic aneurysm. In addition, the ZFP36 gene is used as an action target to prepare or screen a drug for resisting abdominal aortic aneurysm, and the drug has important significance in treatment of abdominal aortic aneurysm.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of ZFP36 gene in preparing anti-abdominal aortic aneurysm medicine, and belongs to the technical field of medicine. Background Art

[0002] Abdominal aortic aneurysm (AAA) is a large vessel disease characterized by structural destruction of the abdominal aorta, local dilation, and an increase in diameter of more than 50% of the normal diameter. Affected by factors such as the accelerated aging of the population in my country and the increasingly prominent unhealthy lifestyle of residents, the incidence of AAA in my country has increased year by year, reaching 9% in men over 65 years old. Most AAAs have an insidious onset and usually have no obvious clinical symptoms. Severe abdominal pain in patients indicates a ruptured aneurysm, and the mortality rate can reach 90%. Although the application of surgical operations and endovascular repair has achieved certain results, there is still a lack of effective drugs to treat and delay the progression of AAA in clinical practice. Therefore, in-depth exploration of the regulatory pathways and mechanisms of AAA progression and the search for effective intervention targets and therapeutic drugs are one of the frontier topics that need to be urgently addressed in the field of cardiovascular research.

[0003] The aneurysmal expansion of the lumen of AAA is often accompanied by pathological changes such as inflammatory cell infiltration, apoptosis of vascular smooth muscle cells (VSMCs), destruction and disorder of elastic fiber structure, and imbalance of synthesis / degradation of extracellular matrix (ECM). VSMCs play an important regulatory role in maintaining vascular homeostasis and the progression and rupture of AAA due to their high plasticity and multidirectional differentiation potential. According to their functional states, VSMCs are divided into different types, of which the two most important types are contractile (differentiated) and synthetic secretory (undifferentiated). VSMCs in normal blood vessels are contractile, with the specific characteristics of high expression of contraction-related proteins such as smooth muscle actin-α (α-smooth muscleactin, α-SMA), myosin heavy chain 11 (myosin heavy chain 11, MYH11) and smooth muscle 22α (smooth muscle 22α, SM22α), and have the ability to maintain vascular tension and regulate vascular contraction. Under the stimulation of many pathological factors, VSMCs redifferentiate into a synthetic secretory phenotype, downregulate the expression of contraction-related proteins, and instead express secretory subtype markers such as osteopontin (OPN), while synthesizing and secreting a variety of pro-inflammatory factors such as matrix metalloproteinases (MMPs) and TNF-α (tumor necrosis factor-α, TNF-α), leading to ECM degradation and VSMC apoptosis, and participating in the formation of AAA. Many studies have confirmed that VSMC phenotypic conversion is an important pathophysiological basis of AAA, and chromatin and transcriptional regulatory elements participate in the progression of AAA by regulating VSMC phenotype-related genes.

[0004] RNA binding proteins (RBPs) are a class of proteins that play an important regulatory role in life activities. By regulating post-transcriptional activities such as alternative splicing, RNA editing, polyadenylation, mRNA localization, and translation, RBPs play an important role in maintaining organ homeostasis and the progression of various systemic diseases. Zinc finger protein 36 (ZFP36, also known as Tristetraprolin, TTP) is a classic RNA binding protein with anti-inflammatory effects. Previous studies have confirmed the role of ZFP36 in alleviating atherosclerotic lesions by inhibiting macrophage foaming and endothelial cell inflammation, but its role in smooth muscle cells and AAA progression is still unclear.

[0005] Conditional gene knockout refers to an experimental technique that knocks out a specific gene in a specific tissue cell or at a specific stage of cell development. Conditional gene knockout generally uses the Cre / loxP recombination system. Cre recombinase is a site-specific recombinase that can mediate specific recombination between two loxP sites, so that the gene sequence between the loxP sites is deleted or recombined. Cre recombinase-mediated recombination between two loxP sites is a dynamic and reversible process, which can be divided into three cases: 1) If the two loxP sites are located on the same DNA chain and in the same direction, Cre recombinase can effectively remove the sequence between the two loxP sites; 2) If the two loxP sites are located on the same DNA chain but in opposite directions, Cre recombinase can cause sequence inversion between the two loxP sites; 3) If the two loxP sites are located on two different DNA chains or chromosomes, Cre recombinase can mediate the exchange of two DNA chains or chromosome translocation. Conditional gene knockout is of great significance for studying the function of specific genes in specific tissue cells and / or at a specific time, as well as for better establishing animal models of human diseases. Summary of the invention

[0006] In view of the deficiencies of the prior art, the present invention provides the use of ZFP36 gene in the preparation of anti-abdominal aortic aneurysm drugs.

[0007] The technical solution of the present invention is as follows:

[0008] The use of ZFP36 gene in the preparation of an anti-abdominal aortic aneurysm drug, wherein the nucleotide sequence of the ZFP36 gene is shown in SEQ ID No. 1.

[0009] Preferably, according to the present invention, the use of the ZFP36 gene in the preparation of an anti-abdominal aortic aneurysm drug includes the following two aspects:

[0010] (1) Using ZFP36 gene as a target for the preparation of anti-abdominal aortic aneurysm drugs;

[0011] (2) The ZFP36 gene was used as a target for the screening of anti-abdominal aortic aneurysm drugs.

[0012] Preferably according to the present invention, the application of the ZFP36 gene as a target in the preparation of anti-abdominal aortic aneurysm drugs means: using the ZFP36 gene as a target of the drug or preparation, increasing the expression level of the smooth muscle cell ZFP36 gene, to develop drugs or preparations for abdominal aortic aneurysm.

[0013] Preferably according to the present invention, the application of the ZFP36 gene as a target in the screening of anti-abdominal aortic aneurysm drugs means: using the ZFP36 gene as a target of drugs or preparations, screening the drugs or preparations to find drugs or preparations that can promote the expression of the ZFP36 gene in smooth muscle cells as alternative drugs or preparations for anti-abdominal aortic aneurysm.

[0014] Preferably according to the present invention, the anti-abdominal aortic aneurysm drug includes but is not limited to: nucleic acid molecules, carbohydrates, lipids, small molecule chemical drugs, antibody drugs, polypeptides, proteins or viruses.

[0015] Further preferably, the nucleic acid molecule includes but is not limited to: antisense oligonucleotide, double-stranded RNA or short hairpin RNA.

[0016] Further preferably, the virus is an adeno-associated virus, the active ingredient of which contains the nucleotide sequence shown in SEQ ID No. 1, is packaged by the virus, and reduces the occurrence of abdominal aortic aneurysm by overexpressing the ZFP36 gene.

[0017] Technical features and beneficial effects of the present invention:

[0018] 1. The present invention constructs a knockout mouse with smooth muscle-specific knockout of ZFP36, and constructs a mouse abdominal aortic aneurysm model by subcutaneously pumping AngII. It is found that knocking out the ZFP36 gene significantly increases the incidence of abdominal aortic aneurysm, while overexpressing the ZFP36 gene can effectively reduce the incidence of abdominal aortic aneurysm and inhibit the occurrence and development of abdominal aortic aneurysm, thereby providing a theoretical basis for preparing or screening drugs or preparations that promote the expression of the smooth muscle cell ZFP36 gene as alternative drugs or preparations for treating abdominal aortic aneurysm.

[0019] 2. The present invention prepared an adeno-associated virus (AAV2-ZFP36) overexpressing the ZFP36 gene and a control adeno-associated virus (AAV2-CTRL), and injected the overexpressed AAV and the control AAV into the tail vein of mice. It was found that specific overexpression of the ZFP36 gene in smooth muscle cells can significantly inhibit the occurrence of abdominal aortic aneurysm in mice.

[0020] 3. The present invention uses the ZFP36 gene as a target to prepare or screen drugs against abdominal aortic aneurysm. Drug screening is mainly aimed at unknown drugs, and the drugs are acted on the target gene. The drugs against abdominal aortic aneurysm are screened according to whether the drugs can promote the expression of the target gene; drug preparation is mainly based on the target gene, and the drugs against abdominal aortic aneurysm are prepared or constructed in a targeted manner to promote the expression of the target gene; the screened or prepared drugs are of great significance in the treatment of abdominal aortic aneurysm. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Flowchart of the strategy for conditional knockout of the ZFP36 gene.

[0022] Figure 2 For ZFP36 ΔSMC The expression of ZFP36 in mouse aorta tissue;

[0023] In the figure, A is the expression of ZFP36 protein in mouse aorta detected by Western blot; B is the expression of ZFP36 mRNA in mouse aorta detected by RT-qPCR; C is the immunofluorescence staining of mouse aorta; ZFP36 flox / flox Representative control mice, ZFP36 ΔSMC represents ZFP36 knockout mice, and β-Tubulin is the internal reference protein.

[0024] Figure 3 For ZFP36 ΔSMC Expression of ZFP36 in mouse aortic smooth muscle cells;

[0025] In the figure, A is the expression of ZFP36 protein in mouse aortic smooth muscle cells detected by Western blot, B is the expression of ZFP36 mRNA in mouse aortic smooth muscle cells detected by RT-qPCR, and C is the immunofluorescence staining identification of mouse aortic smooth muscle cells; ZFP36 flox / flox Representative control mice, ZFP36 ΔSMC represents ZFP36 knockout mice, and β-Tubulin is the internal reference protein.

[0026] Figure 4 For ZFP36 flox / flox Mouse and ZFP36 ΔSMCThe formation of abdominal aortic aneurysms in mice;

[0027] In the figure, A is the process of constructing the mouse abdominal aortic aneurysm model; B is the tumor formation of mouse abdominal aortic aneurysm.

[0028] Figure 5 The tumorigenesis of abdominal aortic aneurysm after tail vein injection of smooth muscle cell-specific adeno-associated virus overexpressing ZFP36 (AAV2-ZFP36) and control adeno-associated virus (AAV2-CTRL) in mice;

[0029] In the figure, A is the process of injecting adeno-associated virus; B is the tumor formation of abdominal aortic aneurysm in mice after injection of adeno-associated virus. DETAILED DESCRIPTION

[0030] The present invention is further described below in conjunction with examples, which are only used to illustrate the present invention but not to limit the scope of protection of the present invention.

[0031] Unless otherwise specified, the drugs and reagents involved in the examples are all common commercially available products; the experimental operations involved in the examples are all carried out according to routine operations in the art unless otherwise specified.

[0032] Example 1. Construction of smooth muscle specific ZFP36 knockout mice

[0033] like Figure 1 The strategy of conditional knockout of ZFP36 gene is shown in FIG. flox / flox The mice were mated with Tagln-Cre mice that specifically expressed Cre recombinase in smooth muscle, and the sequences between the loxP sites were recombined, that is, the ZFP36 gene in the smooth muscle of the mice was knocked out, and ZFP36 was obtained. flox / flox / Tagln-Cre mice, which are mice with smooth muscle-specific knockout of the ZFP36 gene. ΔSMC express.

[0034] Take 8-week-old ZFP36 flox / flox Mice and ZFP36 ΔSMC The aorta of mice was stripped of the aorta adventitia, and the samples were ground with protein lysis buffer. 40 μg of protein was taken for Western blot verification and detected with anti-ZFP36 protein antibody. The results are as follows Figure 2 As shown in A, ZFP36 was found ΔSMC The expression of ZFP36 protein in the aorta of mice was significantly downregulated. At the same time, RNA extracted from vascular tissue was used for gene level verification. The results are as follows Figure 2 As shown in B, ZFP36 was found ΔSMC The expression of ZFP36 in the aorta of mice is extremely low. flox / floxMice and ZFP36 ΔSMC Mouse aorta was identified by immunofluorescence staining. Figure 2 As shown in B, ZFP36 was found ΔSMC ZFP36 expression was significantly reduced in mouse aortic vascular smooth muscle.

[0035] To further verify the success of the knockout strategy, ZFP36 flox / flox Mice and ZFP36 ΔSMC The aortic smooth muscle cells of mice were identified by Western blot, RT-qPCR and immunofluorescence staining. Figure 3 shown.

[0036] Depend on Figure 3 A shows that ZFP36 ΔSMC Most of the ZFP36 gene in the aortic smooth muscle of mice was deleted, and the ZFP36 protein could not be expressed. Figure 3 B shows that ZFP36 ΔSMC The expression of ZFP36 mRNA in mouse aortic smooth muscle was significantly reduced. Figure 3 C shows that ZFP36 ΔSMC The expression of ZFP36 protein in the aortic vascular smooth muscle of mice was significantly downregulated, which fully proved that the present invention successfully constructed a mouse with a smooth muscle-specific knockout of ZFP36 gene, thus providing a good animal model for subsequent research.

[0037] Example 2: Verification that smooth muscle ZFP36 gene deletion accelerates the progression of abdominal aortic aneurysms in mice

[0038] ZFP36 flox / flox Mouse and smooth muscle specific knockout ZFP36 gene constructed in Example 1 ΔSMC The mice were randomly divided into 4 groups, with at least 10 mice in each group, and each group received different treatments as follows:

[0039] For 8-week-old control ZFP36 flox / flox ZFP36 knockout in mice and smooth muscle-specific knockout of ZFP36 ΔSMC The mice were injected with rAAV8-Pcsk9 (2×10 11 vg, available from Shandong Weizhen Biotechnology Co., Ltd.) and fed with Paigen feed to induce hyperlipidemia in mice. Two weeks later, an Alzet micropump was implanted subcutaneously on the back of the mice and equal volumes of AngII or saline were pumped in at a rate of 1000 ng / kg / min for 28 consecutive days to successfully establish a mouse abdominal aortic aneurysm model (the specific process is as follows Figure 4 A).

[0040] Group 1: ZFP36 flox / flox mice, pumped with saline;

[0041] Group 2: ZFP36 flox / flox mice, pumped with AngII;

[0042] Group 3: ZFP36 ΔSMC mice, pumped with saline;

[0043] Group 4: ZFP36 ΔSMC mice, pumped with AngII;

[0044] After 28 days, the mice were euthanized, the aortas of the mice were removed, and the tumor formation rate and aneurysm rupture rate of the mice were recorded. Figure 4 As shown in B, it was found that knocking out the ZFP36 gene could significantly increase the incidence of abdominal aortic aneurysm, which indicates that the ZFP36 gene is directly related to the incidence of abdominal aortic aneurysm. The incidence of abdominal aortic aneurysm can be reduced and the occurrence and development of abdominal aortic aneurysm can be inhibited by overexpressing the ZFP36 gene.

[0045] Example 3: Verification of the inhibition of abdominal aortic aneurysm progression in mice by overexpression of the smooth muscle ZFP36 gene

[0046] 1. Adeno-associated virus (AAV2-ZFP36) and control adeno-associated virus (AAV2-CTRL) that specifically overexpress ZFP36 in smooth muscle cells were constructed by Shandong Weizhen Biotechnology Co., Ltd., with a titer of 2×10 11 vg.

[0047] 2. If Figure 5 As shown in A, C57BL / 6J mice were divided into four groups, with at least 10 mice in each group. At 8 weeks of age, they were treated by tail vein injection of AAV2-ZFP36 and AAV2-CTRL, respectively. Three days later, rAAV8-Pcsk9 (2×10 11 vg, available from Shandong Weizhen Biotechnology Co., Ltd.) and fed with Paigen feed to induce hyperlipidemia in mice. Two weeks later, Alzet micropumps were implanted subcutaneously on the backs of mice and equal volumes of AngII or saline were pumped in at a rate of 1000ng / kg / min for 28 consecutive days. The mice in the four groups and their treatments are as follows:

[0048] Group 1: AAV2-CTRL was injected into the tail vein and normal saline was pumped in;

[0049] Group 2: AAV2-CTRL was injected into the tail vein and AngII was pumped in;

[0050] Group 3: AAV2-ZFP36 was injected into the tail vein and normal saline was pumped in;

[0051] Group 4: AAV2-ZFP36 was injected into the tail vein and AngII was pumped in;

[0052] After continuous pumping for 28 days, the mice were euthanized and the aorta was taken out. The formation of abdominal aortic aneurysm in the mice was as follows: Figure 5 As shown in B.

[0053] Depend on Figure 5 B shows that tail vein injection of adeno-associated virus AAV2-ZFP36 in mice can significantly reduce the volume of abdominal aortic aneurysm, further indicating that specific overexpression of the ZFP36 gene in mouse smooth muscle cells can significantly inhibit the progression of abdominal aortic aneurysm.

[0054] The above results confirm the key role of the ZFP36 gene in inhibiting the occurrence of abdominal aortic aneurysm. Knockout of the ZFP36 gene in smooth muscle can increase the risk of abdominal aortic aneurysm, while specific overexpression of ZFP36 in smooth muscle cells through adeno-associated virus (AAV2-ZFP36) of ZFP36 has a therapeutic effect of inhibiting the occurrence and progression of abdominal aortic aneurysm.

Claims

1. Application of ZFP36 gene in the preparation of anti-abdominal aortic aneurysm drugs, the nucleotide sequence of the ZFP36 gene is shown in SEQ ID No.

1.

2. The use according to claim 1, characterized in that The application of the ZFP36 gene in the preparation of an anti-abdominal aortic aneurysm drug includes the following two aspects: (1) Using ZFP36 gene as a target for the preparation of anti-abdominal aortic aneurysm drugs; (2) The ZFP36 gene was used as a target for the screening of anti-abdominal aortic aneurysm drugs.

3. The use according to claim 2, characterized in that The use of the ZFP36 gene as a target for the preparation of anti-abdominal aortic aneurysm drugs means: using the ZFP36 gene as a target for drugs or preparations to develop drugs or preparations for abdominal aortic aneurysm, thereby increasing the expression level of the ZFP36 gene in smooth muscle cells; or using drugs with the ZFP36 gene as a target for the preparation of anti-abdominal aortic aneurysm drugs.

4. The use according to claim 2, characterized in that The application of the ZFP36 gene as a target in the screening of anti-abdominal aortic aneurysm drugs means: using the ZFP36 gene as a target of drugs or preparations, screening the drugs or preparations to find drugs or preparations that can promote the expression of the smooth muscle cell ZFP36 gene as alternative drugs or preparations for anti-abdominal aortic aneurysm.

5. The use according to claim 1, characterized in that The anti-abdominal aortic aneurysm drugs include, but are not limited to: nucleic acid molecules, carbohydrates, lipids, small molecule chemical drugs, antibody drugs, polypeptides, proteins or viruses.

6. The use according to claim 5, characterized in that The nucleic acid molecule includes, but is not limited to, antisense oligonucleotides, double-stranded RNA or short hairpin RNA.

7. The use according to claim 1, characterized in that The virus is an adeno-associated virus, the active ingredient of which contains the nucleotide sequence shown in SEQ ID No. 1, is packaged by the virus, and reduces the occurrence of abdominal aortic aneurysm by expressing the ZFP36 gene.

Citation Information

Cited By

  • Construction method and application of primary cardiomyopathy animal model

    CN120304358A

  • ShRNA (short hairpin ribonucleic acid) for targeted knockout of Eif2ak2 gene and application

    CN120366311A

  • Leukemia fusion gene detection quality control product and preparation method thereof

    CN122189192A